| abstract |
The present invention relates to an HLA-B57 open conformer or HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of first and second monomers, each monomer comprising the HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. A further aspect of the invention provides a combination drug comprising an HLA-B57Fc open conformer and an immune checkpoint inhibitor and / or a checkpoint agonist agent. Furthermore, the present invention relates to HLA-B57 open-comforters as immunomodulators, particularly in diseases where modulation of diverse immune cell components (eg cytotoxic CD8 + T cells, Treg) is a therapeutic strategy, eg infections. On the use of mer. 【Selection chart】 None |